Skip to main content

Advertisement

Log in

Gingival Enlargement Induced by Drugs

  • Review Article
  • Pharmacoepidemiology
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Gingival enlargement, an abnormal growth of the periodontal tissue, is mainly associated with dental plaque-related inflammation and drug therapy. Its true incidence in the general population is unknown. Gingival enlargement produces aesthetic changes, pain, gingival bleeding and periodontal disorders.

Although gingival overgrowth has been traditionally recognised as an adverse effect of phenytoin therapy, it has recently been reported in association with the use of cyclosporin and calcium antagonists. These 3 classes of drugs produce important changes in fibroblast function, which induce an increase in the extracellular matrix of the gingival connective tissue.

In the majority of those patients for whom dosage reduction, or drug discontinuation or substitution is not possible, and for whom prophylactic measures have failed, surgical excision of gingival tissue remains the only treatment of choice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Carranza FA. Agrandamiento gingival. In: Carranza FA, editor. Periodontologia clínica de Glickman. México: Interamericana McGraw-Hill, 1993: 135–59

    Google Scholar 

  2. Hasseil TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Bio Med 1991; 2: 103–37

    Google Scholar 

  3. Hirschfeld I. Hypertrophic gingivitis: its clinical aspects. J Am Dent Assoc 1932; 19: 799–801

    Google Scholar 

  4. Kimball OP. The treatment of epilepsy with sodium diphenyl-hydantoinate. JAMA 1939; 112: 1244–5

    Google Scholar 

  5. Rateitschak-Plüss E, Heftia A, Lotcher R, et al. Initial observation that cyclosporin-A induces gingival enlargement in man. J Clin Periodontol 1983; 10: 237–46

    PubMed  Google Scholar 

  6. Thomason JM, Seymour RA, Soames JV. Severe mucosal hyperplasia of the edentulous maxilla associated with immunosuppressant therapy: a clinical report. J Prosthet Dent 1994; 72: 1–3

    PubMed  CAS  Google Scholar 

  7. Ramon Y, Behar S, Kishon Y, et al. Gingival hyperplasia caused by nifedipine: a preliminary report. Int J Cardiol 1984; 5: 195–204

    PubMed  CAS  Google Scholar 

  8. Mathis DE, Scheetz AP. Calcium channel antagonists and gingival hyperplasia. Ann Intern Med 1994; 121: 624–5

    PubMed  CAS  Google Scholar 

  9. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992; 63: 453–6

    PubMed  CAS  Google Scholar 

  10. Bowman JM, Levy BA, Grubb RV. Gingival overgrowth induced by diltiazem. Oral Surg Oral Med Oral Pathol 1988; 65: 183–5

    PubMed  CAS  Google Scholar 

  11. Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med 1991; 20: 201–9

    PubMed  CAS  Google Scholar 

  12. Fujii A, Matsumoto H, Nakao S, et al. Effect of calcium-channel blockers on cell proliferation, DNA synthesis and collagen synthesis of cultured gingival fibroblasts derived from human nifedipine responders and non-responders. Arch Oral Biol 1994; 39: 99–104

    PubMed  CAS  Google Scholar 

  13. Angelopoulos AP. A clinicopathological review: diphenylhydantoin gingival hyperplasia. Incidence, clinical features and histopathology. J Can Dent Assoc 1975; 41: 103–6

    CAS  Google Scholar 

  14. Angelopoulos AP. A clinicopathological review: diphenylhydantoin gingival hyperplasia. Aetiology, pathogenesis, differential diagnosis and treatment. J Can Dent Assoc 1975; 41: 275–83

    CAS  Google Scholar 

  15. Hasseil TM, White GG, Jewson LG, et al. Valproic acid: a new antiepileptic drug with potential side effects of dental concern. J Am Dent Assoc 1979; 99: 983–7

    Google Scholar 

  16. Wysocki GP, Gretzinger HA, Laupacis A, et al. Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Surg Oral Med Oral Pathol 1983; 55: 274–8

    PubMed  CAS  Google Scholar 

  17. Delliliers GL, Santoro F, Polli N, et al. Light and electron microscopic study of cyclosporin A-induced gingival hyperplasia. J Periodontol 1986; 57: 771–5

    Google Scholar 

  18. Rostock MH, Fry HR, Turner JE. Severe gingival overgrowth associated with cyclosporin therapy. J Periodontol 1986; 57: 294–9

    PubMed  CAS  Google Scholar 

  19. Hassell T. Evidence that cyclosporin, phenytoin and dihydropiridines elicit overgrowth by different mechanism [abstract 447]. J Dent Res 1990; 69: 164

    Google Scholar 

  20. Peñarrocha-Diago M, Bagan-Sebastian JV, Vera-Sempere F. Diphenylhydantoin-induced gingival overgrowth in man: a clinico-pathological study. J Periodontol 1990; 61: 571–4

    PubMed  Google Scholar 

  21. Mariani G, Calastrini C, Carinci F, et al. Ultrastructural features of cyclosporin A-induced gingival hyperplasia. J Periodontol 1993; 64: 1092–7

    PubMed  CAS  Google Scholar 

  22. Zebrowski EJ, Pylypas SP, Odium O, et al. Comparative metabolism of 3H-glucosamine by fibroblast populations exposed to cyclosporin. J Periodontol 1994; 65: 565–7

    PubMed  CAS  Google Scholar 

  23. Tyldesley WR, Rotter E. Gingival hyperplasia induced by ciclosporin-A. Br Dent J 1984; 157: 305–9

    PubMed  CAS  Google Scholar 

  24. Zebrowski E, Singer D, Brunka J. Cycloporine-A, nifedipine and phenytoin: comparative effects on gingival fibroblast metabolism. J Dent Res 1986; 65: 331–5

    Google Scholar 

  25. Van der Wall E, Tuinzing D, Hiss J. Gingival hyperplasia: a possible side effect of nifedipine. Ned Tijdschn Geneeskd 1984; 128: 1954–5

    Google Scholar 

  26. Panuska HJ, Gorlin RJ, Bearman JE, et al. The effect of anticonvulsant drugs upon the gingiva: a series of analyses of 1048 patients. J Periodontol 1960; 31: 336–44

    Google Scholar 

  27. Syrjanen S, Syrjanen K. Hyperplastic gingivitis in a child receiving sodium valproate treatment. Proc Finn Dent Soc 1979; 75: 95–8

    PubMed  CAS  Google Scholar 

  28. Ciancio SG. Anticonvulsants. In: Holroyd SV, editor. Clinical pharmacology in dental practice. St Louis: Mosby, 1978; 116–20

    Google Scholar 

  29. Greenberg MS. Neuromuscular diseases. In: Lynch MA, editor. Burket’s oral medicine. Philadelphia: JB Lippincott Co., 1977: 500–1

    Google Scholar 

  30. Hassell TM. Epilepsy and the oral manifestations of phenytoin therapy. New York: Karger, 1981

    Google Scholar 

  31. Leppik IE. Antiepileptic medications. Comp Cont Ed Dent 1990; 14: 490–6

    Google Scholar 

  32. Kapur RN, Girgis S, Little TM, et al. Diphenylhydantoin-induced gingival hypertrophy: its relationship to dose and serum level. Dev Med Child Neurol 1973; 15: 483–7

    PubMed  CAS  Google Scholar 

  33. Addy V, McElnay JC, Eyre DG, et al. Risk factors in phenytoin-induced gingival hyperplasia. J Periodontol 1983; 54: 373–7

    PubMed  CAS  Google Scholar 

  34. Perlík F, Kolínová M, Zvárová J, et al. Phenytoin as a risk factor in gingival hyperplasia. Ther Drug Monit 1995; 17: 445–8

    PubMed  Google Scholar 

  35. Hassell TM, O’Donnell J, Pearlman J, et al. Phenytoin-induced gingival overgrowth in institutionalized epileptics. J Clin Periodontol 1984; 11: 242–53

    PubMed  CAS  Google Scholar 

  36. Dahllöf G, Modéer T, Reinholt FP, et al. Proteoglycans and glycosaminoglycans in phenytoin-induced gingival overgrowth. J Periodont Res 1986; 21: 13–21

    PubMed  Google Scholar 

  37. Chee WW, Jansen CE. Phenytoin hyperplasia occurring in relation to titanium implants: a clinical report. Int J Oral Maxillofac Implants 1994; 9: 107–9

    PubMed  CAS  Google Scholar 

  38. Harris TH, Ewalt JR. Complications following the use of sodium diphenylhydantoinate (Dilantin) therapy. J Oklahoma State Med Assoc 1942; 35: 365–70

    Google Scholar 

  39. Livingston S, Livingston H. Diphenylhydantoin gingival hyperplasia. Am J Dis Child 1969; 117: 265–70

    PubMed  CAS  Google Scholar 

  40. Lennox WG. The drug therapy of epilepsy. JAMA 1940; 114: 1347–54

    Google Scholar 

  41. Angelopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1972; 34: 898–906

    PubMed  CAS  Google Scholar 

  42. Delasnerie-Lauprêtre N, Turpin JC. Evaluation of the prevalence of side effects of phenobarbital in the Champagne-Ardenne region (France). Pathol Biol 1991; 39: 780–4

    PubMed  Google Scholar 

  43. Russo L. Valproate-induced stomatitis. Neurology 1981; 31: 329–31

    PubMed  Google Scholar 

  44. Seymour RA, Smith DG, Turnbull DN. The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients. J Clin Periodontol 1985; 12: 413–9

    PubMed  CAS  Google Scholar 

  45. Lundström A, Eeg-Olofsson O, Hamp SE. Effects of anti-epileptic drug treatment with carbamazepine or phenytoin on the oral state of children and adolescents. J Clin Periodontol 1982; 9: 482–8

    PubMed  Google Scholar 

  46. Britton S, Palacios R. Cyclosporin A: usefulness, risks and mechanism of action. Immunologic Rev 1982; 65: 5–21

    CAS  Google Scholar 

  47. Adams D, Davies G. Gingival hyperplasia induced by cyclosporin A. Br Dent J 1984; 157: 89–90

    PubMed  CAS  Google Scholar 

  48. Bennett J, Christian J. Cyclosporin-induced gingival hyperplasia: case report and literature review. J Am Dent Assoc 1985; 111: 272–3

    PubMed  CAS  Google Scholar 

  49. Coley C, Jarvis K, Hasseil T. Effect of cyclosporin-A on human gingival fibroblasts in vitro [abstract 1658]. J Dent Res 1986; 65: 353

    Google Scholar 

  50. Seymour RA, Heasman PA. Adverse drug reactions and the periodontal tissues. In: Seymour RA, Heasman PA, Macgregor IDM, editors. Drugs, diseases, and the periodontium. London: Oxford University Press, 1992: 77–91

    Google Scholar 

  51. Daley TD, Wysocki GP, May C. Clinical and pharmacological correlations in cyclosporin-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1986; 62: 417–21

    PubMed  CAS  Google Scholar 

  52. McGaw T, Lam S, Coates J. Cyclosporin-induced gingival overgrowth: correlation with dental plaque scores, gingivitis scores, and cyclosporin levels in serum and saliva. Oral Surg Oral Med Oral Pathol 1987; 64: 293–7

    PubMed  CAS  Google Scholar 

  53. Camargo PMD. Cyclosporin- and nifedipine-induced gingival enlargement: an overview. J West Soc Periodontal 1989; 37: 57–64

    Google Scholar 

  54. Somacarrera ML, Hernández G, Acero J, et al. Factors related to the incidence and severity of cyclosporin-induced gingival overgrowth in transplant patients. A longitudinal study. J Periodontol 1994; 65: 671–5

    PubMed  CAS  Google Scholar 

  55. Hefti AF, Eshenaur AE, Hasseil TM, et al. Gingival overgrowth in cyclosporin A treated multiple sclerosis patients. J Periodontol 1994; 65: 744–9

    PubMed  CAS  Google Scholar 

  56. Wondimu B, Sandberg J, Modéer T. Gingival overgrowth in renal transplant patients administered cyclosporin A in mixture or in capsule form. A longitudinal study. Clin Transplantation 1996; 10: 71–6

    CAS  Google Scholar 

  57. Friskopp J, Klintmalm G. Gingival enlargement: a comparison between cyclosporin and azathioprine-treated renal allograft recipients. Swed Dent J 1986; 10: 85–92

    PubMed  CAS  Google Scholar 

  58. Friskopp J, Engström P, Sundqvist K. Characterisation of mononuclear cells in cyclosporin-A induced gingival enlargement. Scand J Dent Res 1986; 94: 443–7

    PubMed  CAS  Google Scholar 

  59. Slavin J, Taylor J. Cyclosporin, nifedipine, and gingival hyperplasia [letter]. Lancet 1987; II: 739

    Google Scholar 

  60. Pernu HE, Pernu LM, Knuuttila ML. Effect of periodontal treatment on gingival overgrowth among cyclosporin A-treated renal transplant recipients. J Periodontol 1993; 64: 1098–100

    PubMed  CAS  Google Scholar 

  61. Bokenkamp A, Bohnhorst B, Beier C, et al. Nifedipine aggravates cyclosporin A-induced gingival hyperplasia. Pediatr Nephrol 1994; 8: 181–5

    PubMed  CAS  Google Scholar 

  62. Thomason JM, Seymour RA, Rice N. The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth. J Clin Periodontol 1993; 20: 37–40

    PubMed  CAS  Google Scholar 

  63. King GN, Fullinfaw R, Higgins TJ, et al. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J Clin Periodontol 1993; 20: 286–93

    PubMed  CAS  Google Scholar 

  64. Laupacis A, Canadian Transplant Study Group. Complications of Cy-A therapy compared to azathioprine. Transplant Proc 1983; 15: 2748–53

    Google Scholar 

  65. Allman SD, McWhorter AG, Seale NS. Evaluation of cyclosporin-induced gingival overgrowth in the pediatric transplant patient. Pediatr Dent 1994; 16: 36–40

    PubMed  CAS  Google Scholar 

  66. Neumayer HH, Budde K, Färber L, et al. Conversion to microemulsion cyclosporin in stable renal transplant patients: results after one year. Clin Nephrol 1996; 45: 326–31

    PubMed  Google Scholar 

  67. Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporin in the treatment of psoriasis. Arch Dermatol 1996; 132: 623–9

    PubMed  CAS  Google Scholar 

  68. Tyldesley WR, Rotter E. Gingival hyperplasia induced by cyclosporin A. Br Dent J 1984; 157: 305–9

    PubMed  CAS  Google Scholar 

  69. Seymour RA, Heasman PA. Drugs and periodontium. J Clin Periodontol 1988; 15: 1–16

    PubMed  CAS  Google Scholar 

  70. O’Mesa F, Aneiros J, et al. Gingival overgrowth induced by nifedipine and cyclosporin A. Clinical and morphometric study with image analysis. J Clin Periodontol 1995; 22: 591–7

    Google Scholar 

  71. Beveridge T. Cyclosporin A: clinical results. Transplant Proc 1983; 15: 433–7

    Google Scholar 

  72. Thomason JM, Seymour RA, Soames JV. Severe mucosal hyperplasia of the edentulous maxilla associated with immunosuppressant therapy: a clinical report. J Prosthet Dent 1994; 72: 1–3

    PubMed  CAS  Google Scholar 

  73. Lavarenne J. Side-effects of calcium inhibitors. Therapie 1989; 44: 197–200

    PubMed  CAS  Google Scholar 

  74. Steele RM, Schuna AA, Schreiber RT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994; 120: 663–4

    PubMed  CAS  Google Scholar 

  75. Physician’s Desk Reference. 45th ed. Oradell (NJ): Medical Economics Co. Inc., 1991: 2055–8

  76. Facts and Comparisons. St Louis: Facts and Comparisons Inc., 1991: 149b–50b

  77. Lucas RM, Howell LP, Wall BA. Nifedipine-induced gingival hyperplasia: a histochemical and ultrastructural study. J Periodontol 1985; 56: 211–5

    PubMed  CAS  Google Scholar 

  78. Lederman D, Lumerman H, Reuben S, et al. Gingival hyperplasia associated with nifedipine therapy: report of a case. Oral Surg Oral Med Oral Pathol 1984; 57: 620–2

    PubMed  CAS  Google Scholar 

  79. Ramon Y, Behar S, Kishon Y, et al. Gingival hyperplasia caused by nifedipine: a preliminary report. Int J Cardiol 1984; 5: 195–204

    PubMed  CAS  Google Scholar 

  80. Shaftic AA, Widdup LL, Abate MA, et al. Nifedipine-induced gingival hyperplasia. Drug Intell Clin Pharm 1986; 20: 602–13

    PubMed  CAS  Google Scholar 

  81. Meirnyska A, Abrahamnyska M, Gotsman M. Nifedipine-induced gingival hyperplasia: case reports and literature review. Isr J Med Sci 1989; 25: 453–5

    Google Scholar 

  82. Bencini PL, Crosti C, Sala F, et al. Iperplasia gengivale da nifedipina. Giorn It Derm Vener 1986; 121: 29–31

    CAS  Google Scholar 

  83. Barak S, Engelberg IS, Hiss J. Gingival hyperplasia caused by nifedipine: histopathologic findings. J Periodontol 1987; 58: 639–42

    PubMed  CAS  Google Scholar 

  84. Doria G, Cangemi F, Gulizia M, et al. Su tre casi di iperplasia gengivale in corso di terapia con nifedipina. Minerva Cardioangiol 1990; 38: 97–100

    PubMed  CAS  Google Scholar 

  85. Gonzalez-Jaranay M, Mesa F. Nifedipine induced gingival hyperplasia. Rev Eur Odontoestomatol 1991; 3: 127–30

    PubMed  CAS  Google Scholar 

  86. Garcia Bernai G, Collado A, Ceron A. Hiperplasia gingival como reacción adversa a nifedipina [letter]. Atencion Primaria 1991; 8: 265

    Google Scholar 

  87. Seymour RA. Calcium channel blockers and gingival overgrowth. Br Dent J 1991; 170: 376–9

    PubMed  CAS  Google Scholar 

  88. Bullon P, Machuca P, Martínez-Sahuquillo A, et al. Clinical assessment of gingival hyperplasia in patients treated with nifedipine. J Clin Periodontol 1994; 21: 256–9

    PubMed  CAS  Google Scholar 

  89. Nery EB, Edson RG, Lee KK, et al. Prevalence of nifedipine induced gingival hyperplasia. J Periodontol 1995; 66: 572–8

    PubMed  CAS  Google Scholar 

  90. Fattore L, Stablein M, Bredfeldt G, et al. Gingival hyperplasia: a side effect of nifedipine and diltiazem. Spec Care Dentist 1991; 11: 107–9

    PubMed  CAS  Google Scholar 

  91. Iwakura M, Shibuya Y, Obara Y, et al. Prevalence of gingival hyperplasia in the patients associated with nifedipine (antihypertensive drug) therapy. J Dent Health 1987; 37: 574–5

    Google Scholar 

  92. Katsumi Y, Takahara M, Watanabe Y, et al. Statistical study of incidence of gingival hyperplasia induced by hypotensive drugs. (Ca channel blockers). J Jpn Stomatol Soc 1991; 40: 169–78

    Google Scholar 

  93. Barclay S, Thomason JM, Idle JR, et al. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992; 19: 311–4

    PubMed  CAS  Google Scholar 

  94. Steele R, Schuna A, Schreiber R. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994; 120: 663–4

    PubMed  CAS  Google Scholar 

  95. Brown RS, Sein P, Corio R, et al. Nitrendipine-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1990; 70: 593–6

    PubMed  CAS  Google Scholar 

  96. Nagano S, Ogawa T, Fukuyama S, et al. Influence of nicardipine hydrochlorhide on hypotensive effect and insulin secretion in a patient of hypertensive diabetic mellitus. Jpn Pharmacol Ther 1985; 19: 5309–13

    Google Scholar 

  97. Lombardi T, Fiore-Donno, Belser U, et al. Felodipine-induced gingival hyperplasia: a clinical and histologic study. J Oral Pathol Med 1991; 20: 89–92

    PubMed  CAS  Google Scholar 

  98. Seymour RA, Ellis JS, Thomason JM, et al. Amlodipine-induced gingival overgrowth. J Clin Periodontol 1994; 21: 281–3

    PubMed  CAS  Google Scholar 

  99. Juncadella E, Fandos JM, Alba J, et al. Hiperplasia gingival inducida por amlodipino. Med Clin (Barc) 1994; 103: 358–359

    Google Scholar 

  100. Heijl L, Sundin Y. Nitrendipine-induced gingival overgrowth in dogs. J Periodontol 1988; 60: 104–12

    Google Scholar 

  101. Hashigichi J, Hisatomi M, Watari N, et al. Single and repeated dose toxicity studies on lacidipine in beagle dogs. Jpn Pharmacol Ther 1994; 22: 343–75

    Google Scholar 

  102. Wanner T, Nyska A, Nyska M, et al. Gingival hyperplasia in dogs induced by oxodipine, a calcium channel blocking agent. Toxicol Pathol 1988; 16: 327–32

    Google Scholar 

  103. Cucchi G, Giustianini S, Robustelli F. Gingival hyperplasia caused by verapamil. Ital J Cardiol 1985; 15: 556–7

    CAS  Google Scholar 

  104. Smith M, Glenert U. Gingivhyperplasi forarsaget af behandling med verapamil. Tandlaegebladet 1987; 91: 849–50

    Google Scholar 

  105. Pernu HE, Oikarinen K, Hietanen J, et al. Verapamil-induced gingival overgrowth: a clinical, histologic, and biochemical approach. J Oral Pathol Med 1989; 18: 422–5

    PubMed  CAS  Google Scholar 

  106. Colvard MD, Bishop J, Weissman D, et al. Cardizem-induced gingival hyperplasia. Periodontal Case Rep 1986; 8: 67–8

    PubMed  CAS  Google Scholar 

  107. Giustiniani S, Della Cuna FR, Marien M. Hyperplastic gingivitis during diltiazem therapy. Int J Cardiol 1987; 15: 247–9

    PubMed  CAS  Google Scholar 

  108. Bowman J, Levy B, Grubb R. Gingival overgrowth induced by diltiazem. Oral Surg Oral Med Oral Pathol 1988; 65: 183–5

    PubMed  CAS  Google Scholar 

  109. Lynn BD. ‘The pill’ as an etiologic agent in hypertrophic gingivitis. Oral Surg Oral Med Oral Pathol 1967; 24: 333–4

    PubMed  CAS  Google Scholar 

  110. Kaufman AY. An oral contraceptive as an aetiologic factor in producing hyperplastic gingivitis and a neoplasm of the pregnancy tumour type. Oral Surg Oral Med Oral Pathol 1969; 28: 666–70

    PubMed  CAS  Google Scholar 

  111. Sperber GH. Oral contraceptive hypertrophic gingivitis. J Dent Assoc S Afr 1969; 24: 37–40

    PubMed  CAS  Google Scholar 

  112. Chevallier ME. Mouth manifestations and oral contraceptives. Rev Odontoestomatol Midi Fr 1970; 28: 96–103

    CAS  Google Scholar 

  113. El-Ashiry GM, El-Kafrawy AH, Nasr MF, et al. Comparative study of the influence of pregnancy and oral contraceptives on the gingivae. Oral Surg Oral Med Oral Pathol 1970; 30: 472–5

    PubMed  CAS  Google Scholar 

  114. Das AK, Bhomick S, Dutta A. Oral contraceptives and periodontal disease. J Indian Dent Assoc 1971; 43: 155–8

    PubMed  CAS  Google Scholar 

  115. Hall WB. Dilantin hyperplasia. J Periodontal Res 1965; 4: 36–7

    Google Scholar 

  116. Ciancio SD. Gingival hyperplasia and diphenylhydantoin: a longitudinal study [abstract 65]. J Dent Res 1970; 49

    Google Scholar 

  117. Lopez A, Hernández G, Gold S. Control of gingival enlargement induced by nifedipine [abstract 2037]. J Dent Res 1994; 73: 356

    Google Scholar 

  118. Modéer T, Dahllöf G. Development of phenytoin-induced gingival overgrowth in non-institutionalized epileptic children subjected to different plaque control programs. Acta Odontol Scand 1987; 45: 81–5

    PubMed  Google Scholar 

  119. Seymour RA, Ellis JS, Thomason JM. Drug-induced gingival overgrowth and its management. J R Coll Surg Edinb 1993; 38: 328–32

    PubMed  CAS  Google Scholar 

  120. O’Neil TCA, Figures KH. The effects of Chlorhexidine and mechanical methods of plaque control on the recurrence of gingival hyperplasia in young patients taking phenytoin. Br Dent J 1982; 16: 130–3

    Google Scholar 

  121. Shibly O, Ciancio S, Anderson T, et al. The role of 0.12% clohexidine gluconate in drug-induced hyperplasia [abstract 2034]. J Dent Res 1994; 73: 356

    Google Scholar 

  122. George R, Pack ARC. Inhibition of mitogen-induced lymphoblastic transformation by folate [abstract 40]. J Dent Res 1983; 62: 404

    Google Scholar 

  123. Hermos JA, Adams WH, Liu YK. Mucosa of the small intestine in folate deficient alcoholics. Ann Intern Med 1972; 76: 957–65

    PubMed  CAS  Google Scholar 

  124. Whitehead N, Reyner F, Lindenbaum J. Megaloblastic changes in the cervical epithelium: association with oral contraceptive therapy and reversal with folic acid. JAMA 1973; 226: 1421–4

    PubMed  CAS  Google Scholar 

  125. Olesen OV, Jensen ON. The influence of folic acid on phenytoin DPH (metabolism and the 24 hour fluctuation in urinary output of 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH). Acta Pharmacol Toxicol 1980; 7: 402–13

    Google Scholar 

  126. Girwood RH. Folic acid, its analogues and antagonists. In: Sobotka H, Steward CP, editors. Advances in clinical chemistry. New York: Academic Press, 1960: 235–53

    Google Scholar 

  127. Klipstein FA. Subnormal serum folate and a macrocytosis associated with anticonvulsant drug therapy. Blood 1964; 23: 68–84

    PubMed  CAS  Google Scholar 

  128. Brown RS, Si Stanislao PT, Beaver WT, et al. The administration of folic acid to institutionalized epileptic adults with phenytoin-induced gingival hyperplasia: a double-blind, randomized, placebo-controlled, parallel study. Oral Surg Oral Med Oral Pathol 1991; 71: 655–68

    Google Scholar 

  129. Drew HJ, Vogel RY, Molofsky W, et al. Effect of folate on phenytoin hyperplasia. J Clin Periodontol 1987; 14: 350–6

    PubMed  CAS  Google Scholar 

  130. Wong W, Hodge MG, Lewis A, et al. Resolution of cyclosporin-induced gingival hypertrophy with metronidazole [letter]. Lancet 1994; 343: 986

    PubMed  CAS  Google Scholar 

  131. Wahlstrom E, Zamora JU, Teichman S. Improvement in cyclosporin-associated gingival hyperplasia with azithromycin therapy. New Eng J Med 1995; 332: 753–4

    PubMed  CAS  Google Scholar 

  132. Valsecchi R, Cinelli T. Gingival hyperplasia induced by erythromycin [letter]. Acta Derm Venereol 1992; 72: 157

    PubMed  CAS  Google Scholar 

  133. Staple PH. Some tissue reactions associated with 5, 5-diphenyl-hydantoin (‘dilantin’) sodium therapy [letter]. Br Dent J 1953; 95: 289

    CAS  Google Scholar 

  134. Van der Kwast W. Speculations regarding the nature of gingival hyperplasia due to diphenylhydantoin-sodium. Acta Med Scand 1956; 153: 399–405

    Google Scholar 

  135. Walker CR, Tomich CE, Hutton CE. Treatment of phenytoin-induced gingival hyperplasia by electrosurgery. J Oral Surg 1980; 38: 306–11

    PubMed  Google Scholar 

  136. Daley TD, Wysocki GP. Cyclosporin therapy. Its significance to the periodontist. J Periodontol 1984; 55: 708–12

    PubMed  CAS  Google Scholar 

  137. Pernu HE, Oikarinen K, Hietanen J, et al. Verapamil-induced gingival overgrowth: a clinical, histologic and biochemical approach. J Oral Pathol Med 1989; 18: 422–5

    PubMed  CAS  Google Scholar 

  138. Nishikawa S, Tada H, Hamasaki A, et al. Nifedipine-induced gingival hyperplasia: a clinical and in vitro study. J Periodontol 1991; 62: 30–5

    PubMed  CAS  Google Scholar 

  139. Dahllöf G, Axio E, Modéer T. Regression of phenytoin-induced gingival overgrowth after withdrawal of medication. Swed Dent J 1991; 15: 139–43

    PubMed  Google Scholar 

  140. Piattelli A, Petrelli I, Fanci P. Regression following reduction of daily drug dosage in cyclosporin A-induced gingival overgrowth in bone marrow transplant recipients. Acta Stomatol Belg 1993; 90: 171–6

    PubMed  CAS  Google Scholar 

  141. Livingston S, Livingston HL. Diphenylhydantoin gingival hyperplasia. Am J Dis Child 1969; 117: 265–70

    PubMed  CAS  Google Scholar 

  142. Cohen ES. Gingivectomy and gingivoplasty. In: Cohen ES, editor. Atlas of periodontal surgery. Philadelphia: Lea & Febiger, 1988: 29–40

    Google Scholar 

  143. Genco J, Henry M, Walter D. Cirugia periodontal. In: Genco J, Henry M, Walter D, editors. Periodoncia. Mexico: Inter-americana McGraw Hill, 1993: 597–601

    Google Scholar 

  144. Löe H. Chemical gingivectomy: effect of potassium hydroxide on periodontal tissues. Acta Odontol Scand 1961; 19: 517–37

    PubMed  Google Scholar 

  145. Pick RM, Pecaro BC, Silberman CJ. The laser gingivectomy: the use of the CO2 laser for the removal of phenytoin hyperplasia. J Periodontol 1985; 56: 492–6

    PubMed  CAS  Google Scholar 

  146. Barak S, Kaplan I. The CO2 laser in the excision of gingival hyperplasia caused by nifedipine. J Clin Periodontol 1988; 15: 633–5

    PubMed  CAS  Google Scholar 

  147. Hylton RP. Use of CO2 laser for gingivectomy in a patient with Sturge-Weber disease complicated by dilantin hyperplasia. J Oral Maxillofac Surg 1986; 44: 646–8

    PubMed  CAS  Google Scholar 

  148. Abt E, Wigdor H, Lobraico R, et al. Removal of benign intraoral masses using the CO2 laser. J Am Dent Assoc 1987; 115: 729–31

    PubMed  CAS  Google Scholar 

  149. Kaplan I, Raif J. The Sharplan carbon dioxide laser in clinical surgery: 7 years experience. In: Kaplan I, Raif J, editors. The biomedical laser. New York: Springer-Verlag, 1981: 90–102

    Google Scholar 

  150. Kaplan I, Giller S. CO2 laser surgery. 1st ed. Berlin: Springer-Verlag, 1984: 13–203

    Google Scholar 

  151. Roed-Petersen B. The potential use of CO2-laser gingivectomy for phenytoin-induced gingival hyperplasia in mentally retarded patients. J Clin Periodontol 1993; 20: 729–31

    PubMed  CAS  Google Scholar 

  152. Carruth JAS. Resection of the tongue with the carbon dioxide laser. J Laryngol Otol 1982; 96: 529–43

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Magí Farré.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brunet, L., Miranda, J., Farré, M. et al. Gingival Enlargement Induced by Drugs. Drug-Safety 15, 219–231 (1996). https://doi.org/10.2165/00002018-199615030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199615030-00007

Keywords

Navigation